BACKGROUND: Screening for sensorial impairment is a secondary objective in the context of neurodegenerative diseases, including dementias. For example, olfactory dysfunction is among the first signs of Alzheimer's disease. There has been no study of olfactory function in Irish subjects at risk of dementia. AIM: To investigate olfactory function in non-demented Irish persons, who carry genetic risk factors for dementia. METHODS: Thirty-eight Irish adult subjects, who are at risk of dementia, were recruited. Cognitive performance and olfactory function were assessed and apolipoprotein E (APOE) genotype determined. RESULTS: Three and six subjects had a Mini Mental State Examination (MMSE) and Brief Smell Identification Test (B-SIT) score, respectively, outside the normal range. While five out of the fifteen epsilon-4 allele positive subjects had B-SIT scores outside the normal range, only one out of the twenty-three epsilon-4 allele negative subjects had; the difference in this frequency was significant (P=0.025). There was no significant difference (P=0.266) in the frequency of abnormal MMSE scores between epsilon-4 allele groups. CONCLUSION: Further investigation is required to explore the reasons for the higher prevalence of olfactory dysfunction in epsilon-4 allele positive subjects.
BACKGROUND: Screening for sensorial impairment is a secondary objective in the context of neurodegenerative diseases, including dementias. For example, olfactory dysfunction is among the first signs of Alzheimer's disease. There has been no study of olfactory function in Irish subjects at risk of dementia. AIM: To investigate olfactory function in non-demented Irish persons, who carry genetic risk factors for dementia. METHODS: Thirty-eight Irish adult subjects, who are at risk of dementia, were recruited. Cognitive performance and olfactory function were assessed and apolipoprotein E (APOE) genotype determined. RESULTS: Three and six subjects had a Mini Mental State Examination (MMSE) and Brief Smell Identification Test (B-SIT) score, respectively, outside the normal range. While five out of the fifteen epsilon-4 allele positive subjects had B-SIT scores outside the normal range, only one out of the twenty-three epsilon-4 allele negative subjects had; the difference in this frequency was significant (P=0.025). There was no significant difference (P=0.266) in the frequency of abnormal MMSE scores between epsilon-4 allele groups. CONCLUSION: Further investigation is required to explore the reasons for the higher prevalence of olfactory dysfunction in epsilon-4 allele positive subjects.
Authors: D P Devanand; K S Michaels-Marston; X Liu; G H Pelton; M Padilla; K Marder; K Bell; Y Stern; R Mayeux Journal: Am J Psychiatry Date: 2000-09 Impact factor: 18.112
Authors: T Rodriguez Martin; A M Calella; S Silva; E Munna; P Modena; R Chiesa; S Terrevazzi; R M Ruggieri; R Palermo; F Piccoli; R Confalonieri; P Tiraboschi; C Fragiacomo; P Quadri; U Lucca; G Forloni Journal: Dement Geriatr Cogn Disord Date: 2000 Sep-Oct Impact factor: 2.959
Authors: Robert S Wilson; Julie A Schneider; Lisa L Barnes; Laurel A Beckett; Neelum T Aggarwal; Elizabeth J Cochran; Elizabeth Berry-Kravis; Julie Bach; Jacob H Fox; Denis A Evans; David A Bennett Journal: Arch Neurol Date: 2002-07
Authors: Britto P Nathan; Johnathan Yost; Melissa T Litherland; Robert G Struble; Paul V Switzer Journal: Behav Brain Res Date: 2004-04-02 Impact factor: 3.332
Authors: Linda M Ercoli; Prabha Siddarth; Jennifer J Dunkin; Jennifer Bramen; Gary W Small Journal: J Geriatr Psychiatry Neurol Date: 2003-06 Impact factor: 2.680
Authors: W S Layman; D P McEwen; L A Beyer; S R Lalani; S D Fernbach; E Oh; A Swaroop; C C Hegg; Y Raphael; J R Martens; D M Martin Journal: Hum Mol Genet Date: 2009-03-11 Impact factor: 6.150
Authors: Robert S Wilson; Steven E Arnold; Julie A Schneider; Patricia A Boyle; Aron S Buchman; David A Bennett Journal: Ann N Y Acad Sci Date: 2009-07 Impact factor: 5.691
Authors: Rosebud O Roberts; Teresa J H Christianson; Walter K Kremers; Michelle M Mielke; Mary M Machulda; Maria Vassilaki; Rabe E Alhurani; Yonas E Geda; David S Knopman; Ronald C Petersen Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302